Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.
To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.
Disease | Cross reference | Weighted score | Related literature |
---|
We collected disease MeSH terms mapped to the references associated with tacrolimus
There are no associated biomedical information in the current reference collection.
Associated locations are in red color. Not associated locations are in black.
Location | Cross reference | Weighted score | Related literatures |
---|
Function | Cross reference | Weighted score | Related literatures |
---|
Lipid concept | Cross reference | Weighted score | Related literatures |
---|
Gene | Cross reference | Weighted score | Related literatures |
---|
There are no associated biomedical information in the current reference collection.
Authors | Title | Published | Journal | PubMed Link |
---|---|---|---|---|
Garcia-Criado FJ et al. | Tacrolimus (FK506) down-regulates free radical tissue levels, serum cytokines, and neutrophil infiltration after severe liver ischemia. | 1997 | Transplantation | pmid:9293871 |
Satterthwaite R et al. | Incidence of new-onset hypercholesterolemia in renal transplant patients treated with FK506 or cyclosporine. | 1998 | Transplantation | pmid:9484771 |
Shin BH et al. | Regulation of anti-HLA antibody-dependent natural killer cell activation by immunosuppressive agents. | 2014 | Transplantation | pmid:24342979 |
First MR and Fitzsimmons WE | New drugs to improve transplant outcomes. | 2004 | Transplantation | pmid:15201693 |
Francavilla A et al. | Inhibition of liver, kidney, and intestine regeneration by rapamycin. | 1992 | Transplantation | pmid:1371198 |
Yoon SH et al. | CYP3A and ABCB1 genetic polymorphisms on the pharmacokinetics and pharmacodynamics of tacrolimus and its metabolites (M-I and M-III). | 2013 | Transplantation | pmid:23364483 |
Fujita T et al. | Prolonged survival of rat skin allograft by treatment with FK506 ointment. | 1997 | Transplantation | pmid:9326422 |
Jain AB et al. | Pregnancy after kidney and kidney-pancreas transplantation under tacrolimus: a single center's experience. | 2004 | Transplantation | pmid:15077034 |
Eiras G et al. | Species differences in sensitivity of T lymphocytes to immunosuppressive effects of FK 506. | 1990 | Transplantation | pmid:1694318 |
Ravindran VK et al. | Insulin hyposecretion in nondiabetic, tacrolimus-treated renal transplant recipients more than 6 months posttransplantation. | 2009 | Transplantation | pmid:19543067 |
Kahan BD | An immunosuppressive triumvirate to minimize renal injuries associated with calcineurin antagonist therapy. | 1999 | Transplantation | pmid:10428260 |
Washburn K et al. | Steroid elimination 24 hours after liver transplantation using daclizumab, tacrolimus, and mycophenolate mofetil. | 2001 | Transplantation | pmid:11726831 |
Moxey-Mims MM et al. | Increased incidence of insulin-dependent diabetes mellitus in pediatric renal transplant patients receiving tacrolimus (FK506) | 1998 | Transplantation | pmid:9521193 |
Hytiroglou P et al. | FK506 versus cyclosporine as primary immunosuppressive agent for orthotopic liver allograft recipients. Histologic and immunopathologic observations. | 1993 | Transplantation | pmid:7506452 |
Jordan ML et al. | Long-term results of pancreas transplantation under tacrolius immunosuppression. | 1999 | Transplantation | pmid:10075592 |
Shapiro R et al. | Pediatric renal transplantation under tacrolimus-based immunosuppression. | 1999 | Transplantation | pmid:10075598 |
Butani L et al. | Amelioration of tacrolimus-induced nephrotoxicity in rats using juniper oil. | 2003 | Transplantation | pmid:12883183 |
Min DI et al. | Circadian variation of tacrolimus disposition in liver allograft recipients. | 1996 | Transplantation | pmid:8900327 |
Jindal RM et al. | Diabetogenicity of FK506 versus cyclosporine in liver transplant recipients. | 1994 | Transplantation | pmid:7519799 |
David-Neto E et al. | Longitudinal Pharmacokinetics of Tacrolimus in Elderly Compared With Younger Recipients in the First 6 Months After Renal Transplantation. | 2017 | Transplantation | pmid:27482958 |
Mor E et al. | Reversal of severe FK506 side effects by conversion to cyclosporine-based immunosuppression. | 1994 | Transplantation | pmid:7519800 |
Ciancio G et al. | A randomized long-term trial of tacrolimus/sirolimus versus tacrolimums/mycophenolate versus cyclosporine/sirolimus in renal transplantation: three-year analysis. | 2006 | Transplantation | pmid:16570006 |
Reddy KS et al. | Simultaneous kidney-pancreas transplantation without antilymphocyte induction. | 2000 | Transplantation | pmid:10653379 |
Sood P et al. | Management and outcome of BK viremia in renal transplant recipients: a prospective single-center study. | 2012 | Transplantation | pmid:23018881 |
Jevnikar A et al. | Five-year study of tacrolimus as secondary intervention versus continuation of cyclosporine in renal transplant patients at risk for chronic renal allograft failure. | 2008 | Transplantation | pmid:18852662 |
Ninova D et al. | Acute nephrotoxicity of tacrolimus and sirolimus in renal isografts: differential intragraft expression of transforming growth factor-beta1 and alpha-smooth muscle actin. | 2004 | Transplantation | pmid:15316360 |
Naesens M and Sarwal MM | Monitoring calcineurin inhibitor therapy: localizing the moving target. | 2010 | Transplantation | pmid:20458272 |
Watson MJ et al. | Renal function impacts outcomes after intestinal transplantation. | 2008 | Transplantation | pmid:18622288 |
Murase N et al. | Hamster-to-rat heart and liver xenotransplantation with FK506 plus antiproliferative drugs. | 1993 | Transplantation | pmid:7682735 |
Woodle ES et al. | Tacrolimus therapy for refractory acute renal allograft rejection: definition of the histologic response by protocol biopsies. | 1996 | Transplantation | pmid:8878382 |
McLaren A | Tacrolimus pharmacogenetics: bringing the laboratory into the clinic. | 2003 | Transplantation | pmid:14705621 |
Tanaka A et al. | Living related liver transplantation across ABO blood groups. | 1994 | Transplantation | pmid:7522363 |
Amundsen R et al. | Rimonabant affects cyclosporine a, but not tacrolimus pharmacokinetics in renal transplant recipients. | 2009 | Transplantation | pmid:19384170 |
Ji E et al. | Combinational effect of intestinal and hepatic CYP3A5 genotypes on tacrolimus pharmacokinetics in recipients of living donor liver transplantation. | 2012 | Transplantation | pmid:22992768 |
Klein IH et al. | Different effects of tacrolimus and cyclosporine on renal hemodynamics and blood pressure in healthy subjects. | 2002 | Transplantation | pmid:11907418 |
Ringe B et al. | A novel management strategy of steroid-free immunosuppression after liver transplantation: efficacy and safety of tacrolimus and mycophenolate mofetil. | 2001 | Transplantation | pmid:11258429 |
Singh N et al. | Infectious complications in liver transplant recipients on tacrolimus. Prospective analysis of 88 consecutive liver transplants. | 1994 | Transplantation | pmid:7524204 |
Langrehr JM et al. | Evidence that indefinite survival of small bowel allografts achieved by a brief course of cyclosporine or FK506 is not due to systemic hyporesponsiveness. | 1992 | Transplantation | pmid:1384185 |
McCarthy SA et al. | The effects of immunosuppressive drugs on the regulation of activation-induced apoptotic cell death in thymocytes. | 1992 | Transplantation | pmid:1384186 |
Nakajima K et al. | Prolongation of cardiac xenograft survival in rats treated with 15-deoxyspergualin alone and in combination with FK506. | 1988 | Transplantation | pmid:2454521 |
Hu H et al. | Effect of immunosuppressants on T-cell subsets observed in vivo using carboxy-fluorescein diacetate succinimidyl ester labeling. | 2003 | Transplantation | pmid:12698107 |
Hebert MF et al. | Interpreting tacrolimus concentrations during pregnancy and postpartum. | 2013 | Transplantation | pmid:23274970 |
Fujishiro J et al. | Immunologic benefits of longer graft in rat allogenic small bowel transplantation. | 2005 | Transplantation | pmid:15665767 |
Thai NL et al. | Alemtuzumab induction and tacrolimus monotherapy in pancreas transplantation: One- and two-year outcomes. | 2006 | Transplantation | pmid:17198247 |
Fredericks S and Holt DW | TGF-beta quantitation can be tricky. | 1999 | Transplantation | pmid:10480399 |
Herold KC et al. | Inhibition of glucose-stimulated insulin release from beta TC3 cells and rodent islets by an analog of FK506. | 1993 | Transplantation | pmid:7678356 |
Todo S et al. | Small intestinal transplantation in humans with or without the colon. | 1994 | Transplantation | pmid:7512291 |
Aisa Y et al. | Effects of immunosuppressive agents on magnesium metabolism early after allogeneic hematopoietic stem cell transplantation. | 2005 | Transplantation | pmid:16278584 |
Tanaka J et al. | The immunosuppressive agent FK506 enhances the cytolytic activity of inhibitory natural killer cell receptor (CD94/NKG2A)-expressing CD8 T cells. | 2005 | Transplantation | pmid:16378079 |
Vadivel N et al. | Tacrolimus dose in black renal transplant recipients. | 2007 | Transplantation | pmid:17460575 |